Showing results (931-940 of 977) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|July 21, 2025
Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoodsFilipa Lynce, Xianchen Liu, Benjamin Li, et al.
NPJ Breast Cancer|July 21, 2025
Breast carcinomas associated with microglandular adenosis are linked to germline alterations in homologous recombination-deficiency genesChristopher J Schwartz, Iskender Genco, Matteo Repetto, et al.
NPJ Breast Cancer|May 6, 2025
Breastfeeding attributable fraction of triple negative breast cancer in the USRachel Jaber Chehayeb, Nicole Odzer, Roberta A Albany, et al.
NPJ Breast Cancer|April 26, 2025
MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatmentAyako Nakashoji, Atrayee Bhattacharya, Hiroki Ozawa, et al.
NPJ Breast Cancer|October 24, 2025
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic surveyMasahiro Takada, Shigehira Saji, Takayuki Ueno, et al.
NPJ Breast Cancer|October 3, 2025
Meta-analysis of exome-wide gene burden analysis of breast cancer susceptibility genesJennifer A Collister, Karl Smith-Byrne, Joshua Atkins, et al.
NPJ Breast Cancer|September 30, 2025
Polygenic risk score for breast cancer risk prediction in Asian BRCA1 and BRCA2 pathogenic variants carriersMei-Chee Tai, Joe Dennis, Sue K Park, et al.
NPJ Breast Cancer|October 1, 2025
TRIM39-mediated deubiquitination upregulates RNF168 to evade autophagy-ferroptosis in triple-negative breast cancerXiaoli Yao, Xiong Shen, Yue Fan, et al.
NPJ Breast Cancer|September 29, 2025
Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectivesIrene Valle, Thomas Grinda, Lorenzo Antonuzzo, et al.
NPJ Breast Cancer|August 16, 2025
Bridging the gap: ctDNA, genomics, and equity in breast cancer careJulia Aronson, Manasa Bhatta, Lisa A Carey, et al.
Pageof 98